Most Recent
A court has barred US drug company Merck Sharp & Dohme from denying that an agreement made with German pharmaceutical company Merck KGaA was governed by German law, settling a key question before a trade mark case between the two drug giants goes to trial.
Slater & Gordon is probing a possible class action against Allergan Australia on behalf of women who developed a rare form of lymphoma linked to the company's textured breast implants.
NSW Health is facing a potential class action alleging it underpaid junior medical officers who were denied wages for unscheduled or non-rostered hours worked.
Slater & Gordon has filed a class action against life sciences giant Bayer over allegedly defective contraceptive implants that caused serious side effects, requiring many patients fitted with the devices to have hysterectomies.
The former CEO and director of biotech company Sirtex Medical, Gilman Wong, is facing a maximum ten years in prison after pleading guilty to insider trading.
Country Care Group has criticised the DPP for the "argumentative" tone of the notice setting out its criminal cartel case against the mobility equipment provider, and has secured an order for further clarity from prosecutors.
Novartis has applied to amend its proposed patent for an oral form of multiple sclerosis drug Gilenya, as it appeals an invalidity ruling by IP Australia for lack of inventive step.
Medical device manufacturer American Medical Systems has reasserted that it cannot face claims under Australian consumer laws over its allegedly defective vaginal mesh products because it only supplied the products to a US subsidiary.
A court has found Ariosa Diagnostics infringed a patent held by Sequenom for a noninvasive prenatal genetic test, and ruled one claim of the patent invalid for lack of fair basis.
Poppy processor Palla Pharma has agreed to pay $1.125 million to rival Tasmanian Alkaloids t0 settle a lawsuit alleging infringement of two innovation patents for high codeine-concentrated poppy.